Compare PepsiCo, Inc. (PEP) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Tango Therapeutics Inc. — how do they compare? PepsiCo, Inc. trades at $129.92 (market cap $173.48B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: PepsiCo, Inc. is far larger — about 46.3× Tango Therapeutics Inc.'s market cap, and PepsiCo, Inc. pays a 4.65% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 108 Days and Tango Therapeutics Inc. for 0 Days on average.
| PEP | TNGX | |
|---|---|---|
Market Cap | $173.48B | $3.75B |
Volume | 11,774,872 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $32.90 |
52-Week Low | $123.64 | $7.50 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $214.19B | $2.77B |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $129.27, up 2.01% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $93.93B revenue and 11.09% net margin. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a cautious outlook with 67.4% hold ratings.
PEP offers stable dividend income and consistent profitability, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $142.38 suggests 10% upside potential, but technical weakness and mixed sentiment warrant careful monitoring of North American performance in upcoming earnings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
